Evidence map›Paper›PMID 27335277›Full record

ArticleBlood2016

The genetics of nodal marginal zone lymphoma.

Valeria Spina, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano Cascione, Alessio Bruscaggin, Elisa Spaccarotella, Antony B Holmes, Luca Arcaini, Marco Lucioni and 19 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 4 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 4 syntheses or guidelines pooled it, 177 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Haematologica · 2020
    Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 13 institutions in 3 countries.

Valeria SpinaDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;
Hossein KhiabanianDepartment of Biomedical Informatics and Systems Biology, Columbia University, New York, NY;
Monica MessinaDivision of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;
Sara MontiDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;
Luciano CascioneInstitute of Oncology Research and Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;
Alessio BruscagginDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;
Elisa SpaccarotellaDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;
Antony B HolmesInstitute for Cancer Genetics and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY;
Luca ArcainiDepartment of Hematology-Oncology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy;
Marco LucioniDivision of Pathology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy;
Fabrizio TabbòDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY;
Sakellarios ZairisDepartment of Biomedical Informatics and Systems Biology, Columbia University, New York, NY;
Fary DiopDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;
Michaela CerriDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;
Sabina ChiarettiDivision of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;
Roberto MarascaDivision of Hematology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy;
Maurilio PonzoniAteneo Vita-Salute and Unit of Lymphoid Malignancies, San Raffaele H. Scientific Institute, Milan, Italy;
Silvia DeaglioDepartment of Medical Sciences, University of Torino and Immunogenetics Unit, Human Genetics Foundation, Torino, Italy;
Antonio RamponiDivision of Pathology, Department of Health Sciences, Amedeo Avogadro University of Eastern Piedmont and Maggiore Hospital, Novara, Italy;
Enrico TiacciInstitute of Hematology, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy;
Laura PasqualucciInstitute for Cancer Genetics and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY;
Marco PaulliDivision of Pathology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy;
Brunangelo FaliniInstitute of Hematology, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy;
Giorgio InghiramiDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY; Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies, University of Torino, Torino, Italy; and Department of Pathology, NYU Cancer Center, New York University School of Medicine, New York, NY.
Francesco BertoniInstitute of Oncology Research and Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;
Robin FoàDivision of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;
Raul RabadanDepartment of Biomedical Informatics and Systems Biology, Columbia University, New York, NY;
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;
Davide RossiDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Institute of Oncology Research and Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITColumbia University · USSapienza University of Rome · ITCancer Genetics (United States) · USInstitute of Oncology Research · CHUniversity of Pavia · ITUniversity of Perugia · ITCornell University · USIstituti di Ricovero e Cura a Carattere Scientifico · ITItalian institute for Genomic Medicine · ITNew York University · USUniversity of Modena and Reggio Emilia · ITVita-Salute San Raffaele University · IT

Funding

Topology of Cancer Evolution and HeterogeneityU54CA193313 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO, RABADAN, RAUL · 2015 to 2020
$10.4M
NCI NIH HHS U54 CA193313
6 · The paper itself

Abstract

Nodal marginal zone lymphoma (NMZL) is a rare, indolent B-cell tumor that is distinguished from splenic marginal zone lymphoma (SMZL) by the different pattern of dissemination. NMZL still lacks distinct markers and remains orphan of specific cancer gene lesions. By combining whole-exome sequencing, targeted sequencing of tumor-related genes, whole-transcriptome sequencing, and high-resolution single nucleotide polymorphism array analysis, we aimed at disclosing the pathways that are molecularly deregulated in NMZL and we compare the molecular profile of NMZL with that of SMZL. These analyses identified a distinctive pattern of nonsilent somatic lesions in NMZL. In 35 NMZL patients, 41 genes were found recurrently affected in ≥3 (9%) cases, including highly prevalent molecular lesions of MLL2 (also known as KMT2D; 34%), PTPRD (20%), NOTCH2 (20%), and KLF2 (17%). Mutations of PTPRD, a receptor-type protein tyrosine phosphatase regulating cell growth, were enriched in NMZL across mature B-cell tumors, functionally caused the loss of the phosphatase activity of PTPRD, and were associated with cell-cycle transcriptional program deregulation and increased proliferation index in NMZL. Although NMZL shared with SMZL a common mutation profile, NMZL harbored PTPRD lesions that were otherwise absent in SMZL. Collectively, these findings provide new insights into the genetics of NMZL, identify PTPRD lesions as a novel marker for this lymphoma across mature B-cell tumors, and support the distinction of NMZL as an independent clinicopathologic entity within the current lymphoma classification.

Indexed as

Biomarkers, TumorExomeHigh-Throughput Nucleotide SequencingHumansLymphoma, B-Cell, Marginal ZoneMutationReceptor-Like Protein Tyrosine Phosphatases, Class 2Receptor, Notch2Splenic NeoplasmsBiomarkers, TumorNOTCH2 protein, humanPTPRD protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 2Receptor, Notch2

Identifiers

PMID27335277
PMCPMC5016706
OpenAlexW2462518578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.